Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2301MR)

This product GTTS-WQ2301MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2301MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8845MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ6442MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ12927MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ8162MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ785MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ11072MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ1884MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ6019MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 1275
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW